FY2025 EPS Estimates for Omeros Boosted by Cantor Fitzgerald

Omeros Co. (NASDAQ:OMER) – Research analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for Omeros in a research note issued on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings per share of ($2.04) for the year, up from their previous estimate of ($2.19). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.05).

Other analysts also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, May 13th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, May 16th. Finally, StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Monday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 0.9%

NASDAQ:OMER opened at $3.29 on Wednesday. The stock has a fifty day simple moving average of $6.88 and a 200 day simple moving average of $8.13. The firm has a market capitalization of $191.83 million, a price-to-earnings ratio of -1.42 and a beta of 2.42. Omeros has a 1-year low of $2.97 and a 1-year high of $13.60.

Hedge Funds Weigh In On Omeros

Several institutional investors have recently added to or reduced their stakes in OMER. Truvestments Capital LLC raised its stake in shares of Omeros by 116.5% during the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,972 shares during the period. Quantbot Technologies LP bought a new stake in shares of Omeros during the 4th quarter valued at $46,000. Picton Mahoney Asset Management raised its position in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,388 shares during the period. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.